Publication: Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Authors: Kwonjune J. Seung, Palwasha Khan, Molly F. Franke, Saman Ahmed, Stalbek Aiylchiev, Manzur Alam, Fauziah Asnely Putri, Mathieu Bastard, Wisny Docteur, Gary Gottlieb, Catherine Hewison, Shirajul Islam, Naira Khachatryan, Tinatin Kotrikadze, Uzma Khan, Andargachew Kumsa, Leonid Lecca, Yoseph Melaku Tassew, Nara Melikyan, Ye Yint Naing, Lawrence Oyewusi, Michael Rich, Stephen Wanjala, Askar Yedilbayev, Helena Huerga, and Carole D. Mitnick; for the endTB Study Group

Abstract

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.

Access to the full article - DOI: 10.1093/cid/ciz1084